US20010020043A1 - Method of inhibiting formation of infectious microorganisms - Google Patents
Method of inhibiting formation of infectious microorganisms Download PDFInfo
- Publication number
- US20010020043A1 US20010020043A1 US09/734,444 US73444400A US2001020043A1 US 20010020043 A1 US20010020043 A1 US 20010020043A1 US 73444400 A US73444400 A US 73444400A US 2001020043 A1 US2001020043 A1 US 2001020043A1
- Authority
- US
- United States
- Prior art keywords
- tri
- stilbene
- resveratrol
- hydroxylated
- hydroxylated stilbene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 title claims description 33
- 230000002458 infectious effect Effects 0.000 title claims description 10
- 244000005700 microbiome Species 0.000 title description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Polymers C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims abstract description 50
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 47
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 47
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 46
- 229940016667 resveratrol Drugs 0.000 claims abstract description 46
- 241000588653 Neisseria Species 0.000 claims abstract description 21
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000002245 particle Substances 0.000 claims abstract description 10
- YZRSKFVRNOLGTJ-UHFFFAOYSA-N stilbene Polymers C1(=CC=CC=C1)C=CC1=CC=CC=C1.C1(=CC=CC=C1)C=CC1=CC=CC=C1.C1(=CC=CC=C1)C=CC1=CC=CC=C1 YZRSKFVRNOLGTJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZRIUSVITVGWLSQ-UHFFFAOYSA-N stilbene Polymers C=1C=CC=CC=1C=CC1=CC=CC=C1.C=1C=CC=CC=1C=CC1=CC=CC=C1 ZRIUSVITVGWLSQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 208000009305 pseudorabies Diseases 0.000 claims abstract description 9
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 210000003300 oropharynx Anatomy 0.000 claims description 5
- 210000004392 genitalia Anatomy 0.000 claims description 4
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 4
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 32
- 241000700605 Viruses Species 0.000 description 27
- 230000001717 pathogenic effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 244000052769 pathogen Species 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 241000282887 Suidae Species 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000007330 chocolate agar Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- -1 resveratrol Chemical class 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000001629 stilbenes Chemical class 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 241000933941 bacterium 24 Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000013413 gonococcal conjunctivitis Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 206010030861 ophthalmia neonatorum Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LXOPCHVYWBGPND-VOTSOKGWSA-N 4-[(e)-2-phenylethenyl]benzene-1,2,3-triol Chemical compound OC1=C(O)C(O)=CC=C1\C=C\C1=CC=CC=C1 LXOPCHVYWBGPND-VOTSOKGWSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical class [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241001212279 Neisseriales Species 0.000 description 1
- 206010030972 Oral discharge Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- HSTZMXCBWJGKHG-CENDIDJXSA-N Piceid Natural products OC[C@@H]1O[C@@H](Oc2cc(O)cc(C=Cc3ccc(O)cc3)c2)[C@H](O)[C@H](O)[C@H]1O HSTZMXCBWJGKHG-CENDIDJXSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- WDRFFJWBUDTUCA-UHFFFAOYSA-N chlorhexidine acetate Chemical compound CC(O)=O.CC(O)=O.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WDRFFJWBUDTUCA-UHFFFAOYSA-N 0.000 description 1
- 229960001884 chlorhexidine diacetate Drugs 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 235000013675 iodine Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- HSTZMXCBWJGKHG-OUUBHVDSSA-N piceide Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-OUUBHVDSSA-N 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 1
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- the present invention relates to methods of inhibiting replication of three pathogenic microorganisms, pseudorabies virus, Neisseria gonorrheae, and Neisseria meningiditis.
- Pseudorabies virus a member of the Herpesvirus family, primarily affects swine. Because virus is present in the nasal and oral discharges of infected pigs, infection is usually transmitted between pigs by none to nose contact. Contaminated drinking water and feed buckets may also transmit disease. Clinical symptoms in pigs can vary from undetectable to death. The extent of the symptoms depends on the age and immune status of the animal at the time of infection, the virus dose, route of infection, and strain of virus. Young pigs may be severely affected with a 100% mortality in pigs under 2 weeks of age. Piglets may die suddenly or, prior to death, exhibit symptoms which include fever, loss of appetite, convulsions, and paddling. The severity of clinical signs decreases with age, and older pigs may only experience fever and inappetence of a few days duration.
- pseudorabies is a virus infection, antibiotics have no effect.
- the primary methods for preventing spread of the disease involves treatment of environmental surfaces with agents that inactivate the virus. Examples of such agents are phenolic compounds, quaternary ammonimum compounds, chlorhexidine diacetate, iodines, and 5% sodium hydroxide.
- Vaccines may also be used to control spread of the disease. Additional methods for inhibiting replication of the virus, and thereby controlling the spread of the virus and the severity of the disease in swine exposed to the virus are desirable.
- Neisseria gonorrhea is a gram negative bacterium that is pathogenic in humans. The bacterium is spread from person to person by contact with infected secretions, most often by sexual contact. Once the pathogen is deposited on a mucosal surface, a complex series of molecular interactions occur that result in invasion of mucosal columnar cells. The spectrum of diseases ranges from local infections of the urethral, cervical, rectal and oropharyngeal membranes to invasion of the pelvis or epididymis, to invasion of the blood stream, with or without dissemination to distant organs such as heart valves, joints, and pericardium. The pathogen may also infect the conjunctiva. Gonococcal conjunctivitis is most often contracted by neonates passing through an infected birth canal, although adults can also be infected.
- Neisseria meningiditis another member of the genus Neisseria, is also pathogenic in humans.
- the organism is carried on the nasopharyngeal mucosa of infected individuals and, presumably, is transmitted from person to person through passage of respiratory secretions or aeosolized droplets.
- the organism may cause oropharyngitis, it is primarily a saprophyte that asymptomatically colonizes the majority of human beings sometime during their lives. As with other neisserial species, it can sometimes colonize the genital tract or conjunctiva. On rare occasions, the organism invades the blood stream.
- the present invention provides a new method of inhibiting the formation of infectious pseudorabies virus particles, in a host cell.
- the method involves administering a poly- hydroxylated stilbene, particularly resveratrol, or a derivative thereof to a pseudorabies virus infected host cell.
- the poly-hydroxylated stilbene is administered to the host cell in an amount sufficient to inhibit replication of the virus in the virus-infected host cell.
- Such method is useful for preventing the spread of pseudorabies virus from a virus-infected host cell to a non-infected host cell.
- Such method is also useful for establishing a model system for studying the molecular events that occur during replication of pseudorabies virus.
- the method involves administering a composition comprising a poly-hydroxylated stilbene, preferably a tri-hydroxylated stilbene, or a derivative thereof to a non-human animal prior to or shortly after exposure of the animal to the virus.
- a composition comprising a poly-hydroxylated stilbene, preferably a tri-hydroxylated stilbene, or a derivative thereof to a non-human animal prior to or shortly after exposure of the animal to the virus.
- Such method is useful for reducing the cytopathic effect of a pseudorabies virus infection.
- the present invention also provides a method of inhibiting replication of the gram negative bacteria belonging to the genus Neisseria, particularly Neisseria gonorrhea and Neisseria meningiditis.
- Such method involves contacting the bacterium with a composition containing a tri-hydroxylated stilbene or derivative thereof.
- a composition containing a tri-hydroxylated stilbene or derivative thereof can be used to treat an individual who has come in contact with, e.g., a carrier, or an individual who is expected to come into contact with the bacterium, i.e., an individual who may be exposed to the carrier.
- such method comprises administering a composition comprising a therapeutically effective amount of a tri-hydroxylated stilbene, particularly resveratrol, or a derivative thereof to said subject.
- FIG. 1 is a graph showing the extent of pseudorabies virus replication in virus-infected cells incubated in medium lacking resveratrol or containing 50 ⁇ g/ml of resveratrol.
- tri-hydroxylated stilbenes particularly resveratrol has an antimicrobial effect on select pathogenic microorganisms including pseudorabies virus, Neisseria gonorrhea, and Neisseria meningiditis.
- resveratrol at concentrations ranging from 1 ⁇ g/ml to 200 ⁇ g/ml of solution does not inhibit the growth of Eschericia coli, Staphylococcu aureus, Group A beta-hemolytic Streptococcus, Pseudomonas aeruginosa or Candida albicans.
- the structural skeleton of the compound employed in the present methods i.e., the polyhydroxylated stilbene, comprises two aromatic rings joined by an ethylene bridge.
- the compound is a tri-hydroxystilbene, more preferably 3,5,4′-trihdyroxystilbene, which is also known as resveratrol, or a derivative thereof. Resveratrol in either the cis form or trans form is suitable.
- Derivatives of resveratrol as used herein refers to compounds in which one or two of the hydroxyl functions of resveratrol are replaced with other moieties such as, for example, pterostilbene in which the hydroxyl functions at positions 3 and 5 on the disubstituted aromatic ring are methoxylated.
- pterostilbene in which the hydroxyl functions at positions 3 and 5 on the disubstituted aromatic ring are methoxylated.
- Another example is ⁇ -glucoside derivative polydatin or piceid, in which one of the hydroxyl functions on the disubstituted aromatic ring is replaced with glucose; as well as polymers of the parent compound resveratrol.
- Such polymers have been given the name viniferins.
- the present invention provides a method of inhibiting formation of infectious pseudorabies viral particles in a host cell.
- the method comprises administering a polyhydroxylated stilbene, preferably a tri-hydroxylated stilbene, or a derivative thereof to the host cell.
- the polyhydroxylated stilbene is administered in an amount sufficient to or effective to inhibit replication of the pseudorabis virus within the infected cell.
- the polyhydroxylated stilbene or derivative thereof is administered to the host cell either prior to infection of the host cell with the virus or preferably, within six hours after infection of the host cell with the virus.
- the tri-hydroxylated stilbene or derivative thereof is administered to the host cell by contacting the host cell with or exposing the host cell to a composition comprising the tri-hydroxylated stilbene or derivative thereof.
- the method comprises adding a tri-hydroxylated stilbene to the culture medium of pseudorabies virus-infected host cells.
- the tri-hydroxylated stilbene is added to the medium, preferably before the host cells are infected with the virus or within six hours after the host cells are infected with the virus.
- Good results have been obtained by exposing cultured host cells to the tri-hydroxylated stilbene, resveratrol, at a concentration which is greater than 1 ⁇ g/ml and less than 200 ⁇ g/ml of culture medium.
- pseudorabies replication occurs in phases, with each phase being dependent on the successfiil completion of the prior phase.
- the “immediate early phase” occurs at 1-3 hours after infection and is associated with regulatory and synthetic events.
- the “early phase” occurs 3-6 hours after infection and is also associated with regulatory and synthetic events, particularly the synthesis of virus DNA.
- the “late phase” occurs 6-10 hours after infection and is associated with final synthetic events and assembly of viral components into infections virions.
- Such method is useful for establishing model systems for studying the molecular events that occur during replication of pseudorabies virus.
- mammalian cell cultures incubated in the presence and absence of resveratrol may be used to identify cellular factors that are involved in regulating pseudorabies virus synthetic events.
- Such cell cultures may also be employed to characterize the role of psuedorabies virus gene products in the replication of infectious virus, particularly those proteins and factors whose function are currently unknown.
- the method is used to inhibit the development of or to reduce the severity of a pseudorabies infection in a mammalian subject, particularly a non-human mammalian subject.
- Such method comprises administering a therapeutically effective amount of the tri-hydroxylated stilbene or derivative thereof to a mammalian subject prior to or shortly after exposure to the virus.
- Such method is particularly useful for reducing the severity of infection in a pig and, in some cases, preventing the animal from becoming a carrier. Since transmission among pigs is typically due to nose to nose contact, it is preferred that the tri-hydroxylated stilbene be administered in a composition which enters the pig through the nose or the oropharynx.
- the tri-hydroxylated stilbene may be added to the drinking water or the feed of animals that may have come into contact with or could come into contact with the virus.
- the tri-hydroxylated stilbene may be incorporated into an aerosolizable solution or suspension which is then misted into the nurseries of newborn piglets.
- the present invention provides a method of inhibiting the growth of Neisseria gonnorhea and Neissieria meningiditis.
- the method comprises administering a tri- hydroxylated stilbene, preferably resveratrol, or a derivative thereof to a surface which has come in contact with or could come in contact with the organism.
- the method which comprises administering the tri-hydroxylated stilbene to a mucous membrane of a human subject, may be used to prevent or reduce the symptoms of gonnococcal or meningococcal disease in the human subject.
- the tri-hydoxylated stilbene or derivative thereof may be incorporated into a pharmaceutical composition which is applied to the mucous membrane of a carrier of the bacterium or a person who could come into contact with the carrier.
- compositions used in the present methods comprise a therapeutically effective amount of a tri-hydroxylated stilbene preferably resveratrol or a derivative thereof, and a pharmaceutically acceptable carrier.
- the composition comprises a relatively inert carrier.
- Many such carriers are routinely used and can be identified by reference to pharmaceutical texts. Examples include polyethylene glycols, polypropylene copolymers, and some water soluble gels.
- Such a composition may also contain diluents, fillers, salts, buffers, stabilizers, solubilizers, and other pharmaceutically acceptable materials well known in the art.
- pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the anti-microbial activity of the tri-hydroxylated stilbene or derivative thereof.
- a pharmaceutical composition comprising a therapeutically effective amount of the hydroxylated stilbene, preferably resveratrol, is applied to a potential or actual site of infection in the host subject before or after the host subject is exposed to the bacterium.
- Such composition may be used prophylactically to prevent or reduce the severity of infections of the eye, nose, mouth, throat, oropharynx, genitalia, and rectum.
- dentrifices, mouthwashes, tooth paste or gels, or mouth sprays are used.
- Vaginal or rectal administration may be by the usual carriers such as douches, foams, creams, ointments, jellies, and suppositories, the longer lasting forms being preferred.
- Ocular administration is preferably by ophthalmic ointments or solutions.
- the pharmaceutical composition may further contain other agents which either enhance the activity of the tri-hydroxylated stilbene or complement its activity or use in inhibiting growth of the gonoccocus or meningococcus. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with the tri-hydroxylated stilbene, or to minimize side effects.
- the pharmaceutical composition comprises a solvent for the tri-hydroxylated stilbene or derivative thereof, such as, for example, an alcohol.
- a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, corn oil, or synthetic oils may be added.
- the liquid form of the pharmaceutical composition may further contain a physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.
- suitable pH, isotonicity, and stability is within the skill in the art.
- Administration of the pharmaceutical composition to an uninfected subject is via local administration to a site which has been or may be contacted with the pathogenic organism. It is preferred that the pharmaceutical composition be applied prior to exposure to the targeted pathogen or preferably within 1-24 hours, more preferably within 1-12 hours after exposure of the uninfected subject to the pathogenic organsim.
- Administration of the pharmaceutical composition to a carrier of Neisseria meningiditis is via local administration to the upper respiratory tract, i.e. ororpharynx.
- Administration of the pharmaceutical composition to a carrier of Neisseria gonorrhea is via local administration to the genitalia, rectum, or oropharynx.
- the tri-hydroxylated stilbene preferably resveratrol or a derivative thereof is administered to the host subject in a therapeutically effective amount.
- therapeutically effective amount means the total amount of the tri-hydroxylated stilbene that is sufficient to show a meaningful benefit, i.e., prevention or reduction in the extent of infection by the targeted pathogen or a reduction in the severity of the symptoms that result from infection with the targeted pathogen.
- the dosages of the tri-hydroxylated stilbene, particularly resveratrol, which can prevent or reduce the severity of an infection with pseudorabies virus, Neisseria gonorrhea or Neisseria meningididtis can be determined in view of this disclosure by one of ordinary skill in the art by running routine trials with appropriate controls. Comparison of the appropriate treatment groups to the controls will indicate whether a particular dosage is effective in preventing or reducing the severity of the infection at the levels used in a controlled challenge.
- compositions used to practice the method of the present invention should contain about 0.01 ⁇ g to about 10 ⁇ g, more preferably about 0.1 ⁇ g to about 1 mg, of the tri-hydroxylated stilbene, most preferably from about 10 ⁇ g to about 100 ⁇ g of resveratrol per/ml of the composition.
- a single administration of the composition may be sufficient to ameliorate the pathological effects of the virus or bacteria, it is expected that multiple doses will be preferred.
- resveratrol obtained from Sigma Chemical Co, St. Louis, Mo. were prepared in 100% ethanol and diluted to the final concentration in tissue culture media. The maximum concentration of alcohol in the medium was 0.5%. Controls were treated identically, but were incubated without resveratrol.
- the number of pfu's produced in the control cultures infected with an moi of 1 increases rapidly for 24 hours then slows by 48 hours and 72 hours after infection. At this time, the system is exhausted, i.e., active virus has infected and destroyed not only those cells infected during the initial one hour of incubation but also those cells which became infected with virus released by the initially-infected cells.
- the lack of significant increase observed in the control cultures at 48 and 72 hours after treatment indicates that the virus production has peaked, due to the lack of viable cells in which to reproduce.
- Neisseria gonorrhea was obtained from patients diagnosed with gonorrhea. The authenticity of the bacterium was confirmed utilizing standard microbiological techniques of identification. Cultures of the bacterial isolate were inoculated onto fresh plates and then 24 hours later, a suspension was made from isolated colonies.
- a culture of Neisseria meningiditis was obtained from the American Type Culture Collection. Authenticity of the bacterium was confirmed utilizing standard microbiological techniques of identification. Cultures of the bacterial isolate were inoculated onto fresh plates and then 24 hours later, a suspension was made from isolated colonies.
- IC 50 ⁇ g/ml a IC 100 ⁇ g/ml b Neisseria gonorrhea 25 75 Neisseria meningitidis 100 125 Escherichia coli >200 >200 Staphylococcus aureus >200 >200 Group A Beta Streptococcus >200 >200 Pseudomonas aeruginosa >200 >200 Candida albicans >200 >200
Abstract
Description
- This application is a continuation in part of the co-pending, commonly assigned, U.S. patent application Ser. No. 09/145,039; filed Sep. 1, 1998.
- The present invention relates to methods of inhibiting replication of three pathogenic microorganisms, pseudorabies virus, Neisseria gonorrheae, and Neisseria meningiditis.
- Pseudorabies virus, a member of the Herpesvirus family, primarily affects swine. Because virus is present in the nasal and oral discharges of infected pigs, infection is usually transmitted between pigs by none to nose contact. Contaminated drinking water and feed buckets may also transmit disease. Clinical symptoms in pigs can vary from undetectable to death. The extent of the symptoms depends on the age and immune status of the animal at the time of infection, the virus dose, route of infection, and strain of virus. Young pigs may be severely affected with a 100% mortality in pigs under 2 weeks of age. Piglets may die suddenly or, prior to death, exhibit symptoms which include fever, loss of appetite, convulsions, and paddling. The severity of clinical signs decreases with age, and older pigs may only experience fever and inappetence of a few days duration.
- Since pseudorabies is a virus infection, antibiotics have no effect. The primary methods for preventing spread of the disease involves treatment of environmental surfaces with agents that inactivate the virus. Examples of such agents are phenolic compounds, quaternary ammonimum compounds, chlorhexidine diacetate, iodines, and 5% sodium hydroxide. Vaccines may also be used to control spread of the disease. Additional methods for inhibiting replication of the virus, and thereby controlling the spread of the virus and the severity of the disease in swine exposed to the virus are desirable.
- Neisseria gonorrhea is a gram negative bacterium that is pathogenic in humans. The bacterium is spread from person to person by contact with infected secretions, most often by sexual contact. Once the pathogen is deposited on a mucosal surface, a complex series of molecular interactions occur that result in invasion of mucosal columnar cells. The spectrum of diseases ranges from local infections of the urethral, cervical, rectal and oropharyngeal membranes to invasion of the pelvis or epididymis, to invasion of the blood stream, with or without dissemination to distant organs such as heart valves, joints, and pericardium. The pathogen may also infect the conjunctiva. Gonococcal conjunctivitis is most often contracted by neonates passing through an infected birth canal, although adults can also be infected.
- The quest for a gonococcal vaccine has been ongoing for many years with virtually no success. Accordingly, the primary treatment involves preexposure or postexposure antibiotic prophylaxis. In addition to antibiotic eyedrops, silver nitrate has also been used to treat neonatal gonococcal conjunctivitis. Unfortunately, the bacterium has developed resistance to some of the most common antibiotics, such as penicillin. Accordingly, additional compositions for reducing growth of this pathogen is desirable.
- Neisseria meningiditis, another member of the genus Neisseria, is also pathogenic in humans. The organism is carried on the nasopharyngeal mucosa of infected individuals and, presumably, is transmitted from person to person through passage of respiratory secretions or aeosolized droplets. Although the organism may cause oropharyngitis, it is primarily a saprophyte that asymptomatically colonizes the majority of human beings sometime during their lives. As with other neisserial species, it can sometimes colonize the genital tract or conjunctiva. On rare occasions, the organism invades the blood stream. Once the organism has invaded the blood stream, an overlapping array of clinical outcomes ranging from a transient bacteremia, to invasion of the meninges, and encephalitis can occur. Treatment primarily involves administration of antibiotics. Vaccines are also used to prevent infection. Unfortunately, the bacterium may develop resistance to the antibiotics. Moreover, the duration of immunity with the currently available vaccines is limited. Accordingly, it is desirable to have new methods for preventing or inhibiting growth of Neisseria meningiditis.
- The present invention provides a new method of inhibiting the formation of infectious pseudorabies virus particles, in a host cell. The method involves administering a poly- hydroxylated stilbene, particularly resveratrol, or a derivative thereof to a pseudorabies virus infected host cell. The poly-hydroxylated stilbene is administered to the host cell in an amount sufficient to inhibit replication of the virus in the virus-infected host cell. Such method is useful for preventing the spread of pseudorabies virus from a virus-infected host cell to a non-infected host cell. Such method is also useful for establishing a model system for studying the molecular events that occur during replication of pseudorabies virus. In vivo, the method involves administering a composition comprising a poly-hydroxylated stilbene, preferably a tri-hydroxylated stilbene, or a derivative thereof to a non-human animal prior to or shortly after exposure of the animal to the virus. Such method is useful for reducing the cytopathic effect of a pseudorabies virus infection.
- The present invention also provides a method of inhibiting replication of the gram negative bacteria belonging to the genus Neisseria, particularly Neisseria gonorrhea and Neisseria meningiditis. Such method involves contacting the bacterium with a composition containing a tri-hydroxylated stilbene or derivative thereof. In vivo, such method can be used to treat an individual who has come in contact with, e.g., a carrier, or an individual who is expected to come into contact with the bacterium, i.e., an individual who may be exposed to the carrier. In vivo, such method comprises administering a composition comprising a therapeutically effective amount of a tri-hydroxylated stilbene, particularly resveratrol, or a derivative thereof to said subject.
- FIG. 1 is a graph showing the extent of pseudorabies virus replication in virus-infected cells incubated in medium lacking resveratrol or containing 50 μg/ml of resveratrol.
- In accordance with the present invention, it has been discovered that tri-hydroxylated stilbenes, particularly resveratrol has an antimicrobial effect on select pathogenic microorganisms including pseudorabies virus, Neisseria gonorrhea, and Neisseria meningiditis. In accordance with the present invention, it has also been shown that resveratrol at concentrations ranging from 1 μg/ml to 200 μg/ml of solution does not inhibit the growth of Eschericia coli, Staphylococcu aureus, Group A beta-hemolytic Streptococcus, Pseudomonas aeruginosa or Candida albicans.
- The structural skeleton of the compound employed in the present methods, i.e., the polyhydroxylated stilbene, comprises two aromatic rings joined by an ethylene bridge. Preferably, the compound is a tri-hydroxystilbene, more preferably 3,5,4′-trihdyroxystilbene, which is also known as resveratrol, or a derivative thereof. Resveratrol in either the cis form or trans form is suitable. Derivatives of resveratrol as used herein refers to compounds in which one or two of the hydroxyl functions of resveratrol are replaced with other moieties such as, for example, pterostilbene in which the hydroxyl functions at positions 3 and 5 on the disubstituted aromatic ring are methoxylated. Another example is β-glucoside derivative polydatin or piceid, in which one of the hydroxyl functions on the disubstituted aromatic ring is replaced with glucose; as well as polymers of the parent compound resveratrol. Such polymers have been given the name viniferins. Methods for producing the hydroxylated stilbenes are described in Moreana-Manas, M. et al, Anal Quim (1985) 81:157-161; Jeandet, P. et al, Am J. Enol Vitic (1991) 42:41-6; Goldberg DM et al. Anal Chem (1994) 66:3959-63, Murakami, S et al, Biochem Pharmacol. (1992) 44:1947-51; and Thakkar, K et al, J. Med Chem (1993) 36:2650-51, which are incorporated herein by reference. Resveratrol and 3,3′,4,5′-tetrahydroxy-trans-stilbene, known as piceatoannol, are also available commercially from Sigma Chemical Co., St. Louis, Mo.
- Methods of Inhibiting Formation of Infectious Pseudorabies Viral Particles
- In one aspect, the present invention provides a method of inhibiting formation of infectious pseudorabies viral particles in a host cell. The method comprises administering a polyhydroxylated stilbene, preferably a tri-hydroxylated stilbene, or a derivative thereof to the host cell. The polyhydroxylated stilbene is administered in an amount sufficient to or effective to inhibit replication of the pseudorabis virus within the infected cell. Preferably, the polyhydroxylated stilbene or derivative thereof is administered to the host cell either prior to infection of the host cell with the virus or preferably, within six hours after infection of the host cell with the virus.
- Preferably, the tri-hydroxylated stilbene or derivative thereof is administered to the host cell by contacting the host cell with or exposing the host cell to a composition comprising the tri-hydroxylated stilbene or derivative thereof. For example, in vitro, the method comprises adding a tri-hydroxylated stilbene to the culture medium of pseudorabies virus-infected host cells. In the case of cultured cells, the tri-hydroxylated stilbene is added to the medium, preferably before the host cells are infected with the virus or within six hours after the host cells are infected with the virus. Good results have been obtained by exposing cultured host cells to the tri-hydroxylated stilbene, resveratrol, at a concentration which is greater than 1 μg/ml and less than 200 μg/ml of culture medium.
- It has been determined that treatment of cultured cells in accordance with the present method is non-toxic to cells and blocks replication of pseudorabies virus at some early stage in it replicative cycle. It has also been determined that the effect of resveratrol on pseudorabies virus replication is reversible. Typical of the herpes viruses, pseudorabies replication occurs in phases, with each phase being dependent on the successfiil completion of the prior phase. The “immediate early phase” occurs at 1-3 hours after infection and is associated with regulatory and synthetic events. The “early phase” occurs 3-6 hours after infection and is also associated with regulatory and synthetic events, particularly the synthesis of virus DNA. The “late phase” occurs 6-10 hours after infection and is associated with final synthetic events and assembly of viral components into infections virions. Such method is useful for establishing model systems for studying the molecular events that occur during replication of pseudorabies virus. For example, mammalian cell cultures incubated in the presence and absence of resveratrol may be used to identify cellular factors that are involved in regulating pseudorabies virus synthetic events. Such cell cultures may also be employed to characterize the role of psuedorabies virus gene products in the replication of infectious virus, particularly those proteins and factors whose function are currently unknown.
- In vivo, the method is used to inhibit the development of or to reduce the severity of a pseudorabies infection in a mammalian subject, particularly a non-human mammalian subject. Such method comprises administering a therapeutically effective amount of the tri-hydroxylated stilbene or derivative thereof to a mammalian subject prior to or shortly after exposure to the virus. Such method is particularly useful for reducing the severity of infection in a pig and, in some cases, preventing the animal from becoming a carrier. Since transmission among pigs is typically due to nose to nose contact, it is preferred that the tri-hydroxylated stilbene be administered in a composition which enters the pig through the nose or the oropharynx. For example, the tri-hydroxylated stilbene may be added to the drinking water or the feed of animals that may have come into contact with or could come into contact with the virus. In addition, the tri-hydroxylated stilbene may be incorporated into an aerosolizable solution or suspension which is then misted into the nurseries of newborn piglets.
- Method of Inhibiting Growth of Neisseria gonorrheae or Neisseria meningiditis
- In another aspect, the present invention provides a method of inhibiting the growth of Neisseria gonnorhea and Neissieria meningiditis. The method comprises administering a tri- hydroxylated stilbene, preferably resveratrol, or a derivative thereof to a surface which has come in contact with or could come in contact with the organism. In vivo, the method, which comprises administering the tri-hydroxylated stilbene to a mucous membrane of a human subject, may be used to prevent or reduce the symptoms of gonnococcal or meningococcal disease in the human subject. The tri-hydoxylated stilbene or derivative thereof may be incorporated into a pharmaceutical composition which is applied to the mucous membrane of a carrier of the bacterium or a person who could come into contact with the carrier.
- Pharmaceutical compositions used in the present methods comprise a therapeutically effective amount of a tri-hydroxylated stilbene preferably resveratrol or a derivative thereof, and a pharmaceutically acceptable carrier. Preferably, the composition comprises a relatively inert carrier. Many such carriers are routinely used and can be identified by reference to pharmaceutical texts. Examples include polyethylene glycols, polypropylene copolymers, and some water soluble gels. Such a composition may also contain diluents, fillers, salts, buffers, stabilizers, solubilizers, and other pharmaceutically acceptable materials well known in the art. The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of the anti-microbial activity of the tri-hydroxylated stilbene or derivative thereof.
- In practicing the present method, a pharmaceutical composition comprising a therapeutically effective amount of the hydroxylated stilbene, preferably resveratrol, is applied to a potential or actual site of infection in the host subject before or after the host subject is exposed to the bacterium. Such composition may be used prophylactically to prevent or reduce the severity of infections of the eye, nose, mouth, throat, oropharynx, genitalia, and rectum. In the case of oral administration, dentrifices, mouthwashes, tooth paste or gels, or mouth sprays are used. Vaginal or rectal administration may be by the usual carriers such as douches, foams, creams, ointments, jellies, and suppositories, the longer lasting forms being preferred. Ocular administration is preferably by ophthalmic ointments or solutions.
- The pharmaceutical composition may further contain other agents which either enhance the activity of the tri-hydroxylated stilbene or complement its activity or use in inhibiting growth of the gonoccocus or meningococcus. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with the tri-hydroxylated stilbene, or to minimize side effects.
- Preferably the pharmaceutical composition comprises a solvent for the tri-hydroxylated stilbene or derivative thereof, such as, for example, an alcohol. A liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, corn oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain a physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. The preparation of such pharmaceutical composition having suitable pH, isotonicity, and stability, is within the skill in the art.
- Administration of the pharmaceutical composition to an uninfected subject is via local administration to a site which has been or may be contacted with the pathogenic organism. It is preferred that the pharmaceutical composition be applied prior to exposure to the targeted pathogen or preferably within 1-24 hours, more preferably within 1-12 hours after exposure of the uninfected subject to the pathogenic organsim.
- Administration of the pharmaceutical composition to a carrier of Neisseria meningiditis is via local administration to the upper respiratory tract, i.e. ororpharynx. Administration of the pharmaceutical composition to a carrier of Neisseria gonorrhea is via local administration to the genitalia, rectum, or oropharynx.
- The tri-hydroxylated stilbene, preferably resveratrol or a derivative thereof is administered to the host subject in a therapeutically effective amount. As used herein, the term “therapeutically effective amount” means the total amount of the tri-hydroxylated stilbene that is sufficient to show a meaningful benefit, i.e., prevention or reduction in the extent of infection by the targeted pathogen or a reduction in the severity of the symptoms that result from infection with the targeted pathogen. The dosages of the tri-hydroxylated stilbene, particularly resveratrol, which can prevent or reduce the severity of an infection with pseudorabies virus, Neisseria gonorrhea or Neisseria meningididtis can be determined in view of this disclosure by one of ordinary skill in the art by running routine trials with appropriate controls. Comparison of the appropriate treatment groups to the controls will indicate whether a particular dosage is effective in preventing or reducing the severity of the infection at the levels used in a controlled challenge.
- It is contemplated that the various compositions used to practice the method of the present invention should contain about 0.01 μg to about 10 μg, more preferably about 0.1 μg to about 1 mg, of the tri-hydroxylated stilbene, most preferably from about 10 μg to about 100 μg of resveratrol per/ml of the composition. Although a single administration of the composition may be sufficient to ameliorate the pathological effects of the virus or bacteria, it is expected that multiple doses will be preferred.
- The following examples of methods of using resveretrol to block formation of infectious psuedorabies virus particles and growth of Neisseria gonorrhea and Neisseria meningiditis in vitro are for purposes of illustration only and are not intended to limit the scope of the claims which are appended hereto.
- Inhibiting Formation of Infectious Pseudorabies Particles by Treatment with Resveratrol
- Cultures of African green monkey kidney cells (Vero) cells, obtained from the American Type Culture Collection, Rockville, Md., were grown to confluence in Medium 199 supplemented with 5% fetal bovine serum, 0.075% NaHCO3, and 50 μg/ml gentamycin sulfate in 25 cm2 tissue culture flasks. Cells were infected with pseudorabies virus at a multiplicity of infection (moi) of one and incubated at room temperature for one hour to allow for virus attachment to and penetration of the cell. Under these conditions, approximately half of the cells are infected with virus. Thereafter, the cultures were rinsed three time with media and incubated in medium containing resveratrol at a final concentration of 50 μg/ml. Stock solutions of the resveratrol, obtained from Sigma Chemical Co, St. Louis, Mo. were prepared in 100% ethanol and diluted to the final concentration in tissue culture media. The maximum concentration of alcohol in the medium was 0.5%. Controls were treated identically, but were incubated without resveratrol.
- Upon addition of the medium to the cultures and at 24 hours time periods thereafter, i.e., 0 hours, 24 hours, 48 hours, and 72 hours after addition of the drug, cells and medium were frozen at −70° C. Samples were then thawed, sonicated and titrated in Vero cells to determine the number of plaque forming units (pfu's) of virus produced by each culture.
- As shown in FIG. 1, the number of pfu's produced in the control cultures infected with an moi of 1 increases rapidly for 24 hours then slows by 48 hours and 72 hours after infection. At this time, the system is exhausted, i.e., active virus has infected and destroyed not only those cells infected during the initial one hour of incubation but also those cells which became infected with virus released by the initially-infected cells. The lack of significant increase observed in the control cultures at 48 and 72 hours after treatment indicates that the virus production has peaked, due to the lack of viable cells in which to reproduce.
- As shown in FIG. 1, treatment of cells with 50 μg/ml of resveratrol inhibited formation of infectious virus particles in pseudorabies virus infected cells by more than 99% at 24 hours. By 72 hours, infectious pseudorabies virus particles were virtually undetectable in cultures continuously incubated in the presence of 50 μg/ml of resveratrol.
- Inhibiting Growth of Neisseria gonorrhea by Treatment with Resveratrol
- Stock solutions of the resveratrol, obtained from Sigma Chemical Co, St. Louis, Mo. were prepared in 100% ethanol. Different quantities of the stock solution where added to melted chocolate agar which was then poured into a petri dish and allowed to solidify. The final concentration of resveratrol in the agar ranged from 1 μg to 200 μg/ml. The final concentration of ethanol in the agar was 0.5%. Control plates containing chocolate agar and ethanol at a final concentration of 0.5% were also prepared.
- Neisseria gonorrhea was obtained from patients diagnosed with gonorrhea. The authenticity of the bacterium was confirmed utilizing standard microbiological techniques of identification. Cultures of the bacterial isolate were inoculated onto fresh plates and then 24 hours later, a suspension was made from isolated colonies.
- 10 μl aliquots of the suspension were spread evenly across the surface of samples of solidified control chocolate agar lacking resveratrol and samples of the chocolate agar containing resveratrol at final concentrations ranging from 1 to 200 μg/ml. Thereafter, the samples were incubated at 37° C. with or without 5% CO2. All samples were visually examined for growth of the
bacterium 24 hours later to determine the concentration of resveratol that inhibits growth by 50% (MIC50) as well as the concentration which inhibits any visible growth (MIC100) - Inhibiting Growth of Neisseria meningiditis by Treatment with Resveratrol
- A culture of Neisseria meningiditis was obtained from the American Type Culture Collection. Authenticity of the bacterium was confirmed utilizing standard microbiological techniques of identification. Cultures of the bacterial isolate were inoculated onto fresh plates and then 24 hours later, a suspension was made from isolated colonies.
- 10 μl aliquots of the suspension were spread evenly across the surface of samples of solidified control chocolate agar lacking resveratrol and samples of the chocolate agar containing resveratrol at final concentrations ranging from 1 to 200 μg/ml. Thereafter, the samples were incubated at 37° C. with or without 5% CO2. All samples were visually examined for growth of the
bacterium 24 hours later to determine the resveratrol concentration that inhibits growth by 50% (MIC50) and the resveratrol concentration which inhibits any visible growth (MIC100) - The results, shown in Table 1 below, demonstrate that resveratrol at a concentration of 25 μg/ml inhibited growth of Neisseria gonorrhoeae by 50%, while resveratrol at a concentration of 75 μg/ml inhibited growth of this pathogen by 100%. Resveratrol at a concentration of 100 μg/ml inhibited growth of Neisseria meningiditis by 50%, while resveratrol at a concentration of 125 μg/ml inhibited growth of this pathogen by 100%.
TABLE 1 The Inhibitory Concentration (IC) of Resveretrol on Bacteria and Yeast In Vitro Microorganism IC50μg/mla IC100μg/mlb Neisseria gonorrhea 25 75 Neisseria meningitidis 100 125 Escherichia coli >200 >200 Staphylococcus aureus >200 >200 Group A Beta Streptococcus >200 >200 Pseudomonas aeruginosa >200 >200 Candida albicans >200 >200
Claims (19)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/734,444 US6355692B2 (en) | 1998-09-01 | 2000-12-11 | Method of inhibiting formation of infectious microorganisms |
US10/013,760 US7037945B2 (en) | 2000-12-11 | 2001-12-11 | Method of inhibiting formation of Neisseria gonorrhea and Neisseria meningiditis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/145,039 US6197834B1 (en) | 1998-09-01 | 1998-09-01 | Method of inhibiting formation of infectious herpes virus particles |
US09/734,444 US6355692B2 (en) | 1998-09-01 | 2000-12-11 | Method of inhibiting formation of infectious microorganisms |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/145,039 Continuation-In-Part US6197834B1 (en) | 1998-09-01 | 1998-09-01 | Method of inhibiting formation of infectious herpes virus particles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/013,760 Continuation US7037945B2 (en) | 2000-12-11 | 2001-12-11 | Method of inhibiting formation of Neisseria gonorrhea and Neisseria meningiditis |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010020043A1 true US20010020043A1 (en) | 2001-09-06 |
US6355692B2 US6355692B2 (en) | 2002-03-12 |
Family
ID=22511324
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/145,039 Expired - Fee Related US6197834B1 (en) | 1998-09-01 | 1998-09-01 | Method of inhibiting formation of infectious herpes virus particles |
US09/734,444 Expired - Fee Related US6355692B2 (en) | 1998-09-01 | 2000-12-11 | Method of inhibiting formation of infectious microorganisms |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/145,039 Expired - Fee Related US6197834B1 (en) | 1998-09-01 | 1998-09-01 | Method of inhibiting formation of infectious herpes virus particles |
Country Status (4)
Country | Link |
---|---|
US (2) | US6197834B1 (en) |
AU (1) | AU746756B2 (en) |
CA (1) | CA2342582C (en) |
WO (1) | WO2000012534A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599945B2 (en) | 2000-08-15 | 2003-07-29 | Northeastern Ohio Universities College Of Medicine | Methods for treating subjects infected with a herpes virus |
US20050267023A1 (en) * | 2002-08-09 | 2005-12-01 | Sinclair David A | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
US7544497B2 (en) | 2003-07-01 | 2009-06-09 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US9241916B2 (en) | 2005-06-14 | 2016-01-26 | President And Fellows Of Harvard College | Cognitive performance with sirtuin activators |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
US6197834B1 (en) | 1998-09-01 | 2001-03-06 | Northeastern Ohio Universities College Of Medicine | Method of inhibiting formation of infectious herpes virus particles |
JP2002527361A (en) * | 1998-10-09 | 2002-08-27 | チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド | Hydroxystilbene compounds as fungicidal agents |
US6716883B1 (en) * | 1998-12-24 | 2004-04-06 | 1333366 Ontario Inc. | Composition useful to treat periodontal disease |
PE20010540A1 (en) * | 1999-07-30 | 2001-05-15 | Procter & Gamble | COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES |
US7037945B2 (en) * | 2000-12-11 | 2006-05-02 | Northeastern Ohio Universities College Of Medicine | Method of inhibiting formation of Neisseria gonorrhea and Neisseria meningiditis |
CN1398838A (en) * | 2001-07-26 | 2003-02-26 | 中国人民解放军军事医学科学院放射医学研究所 | Diphenylethylene compound and its prepn and application in preventing and treating diabetes |
WO2003066581A1 (en) * | 2002-02-05 | 2003-08-14 | Eli Lilly And Company | Urea linker derivatives for use as ppar modulators |
US7705188B2 (en) * | 2002-04-10 | 2010-04-27 | Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University | Structural modification of resveratrol: sodium resverastatin phosphate |
US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
CA2548671C (en) * | 2003-12-29 | 2015-02-24 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
US20060014705A1 (en) * | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
US20060088612A1 (en) * | 2004-09-02 | 2006-04-27 | Sivak Hannah N | Composition for treatment of topical infection and methods of making and using same |
AU2006210117B2 (en) | 2005-02-04 | 2011-07-21 | Peter Heger | Method for producing a drug extract that contains hydroxystilbene |
ITRM20050446A1 (en) * | 2005-08-19 | 2007-02-20 | Tubilux Pharma S P A | USE OF HYDROXYLATED AND GLUCOSIDATED STYLBENES FOR THE PREVENTION AND TREATMENT OF EYE PATHOLOGIES. |
US20080103103A1 (en) * | 2006-10-30 | 2008-05-01 | Bahram Memarzadeh | Reagents and methods to treat ocular diseases and infection |
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
US8815936B2 (en) | 2008-03-03 | 2014-08-26 | Nad Life Pty Ltd | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
CA2629979A1 (en) * | 2008-04-25 | 2009-10-25 | Pharmascience Inc. | Novel resveratrol compositions |
US20130338178A1 (en) * | 2011-02-02 | 2013-12-19 | The Trustees Of Princeton University | Sirtuin modulators as inhibitors of cytomegalovirus |
CA2902225A1 (en) * | 2013-02-28 | 2014-09-04 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
US10045950B2 (en) | 2015-04-08 | 2018-08-14 | BioMendics, LLC | Formulation and process for modulating wound healing |
ES2673942B1 (en) * | 2016-11-23 | 2019-04-09 | Consejo Superior Investigacion | ACRYLIC COMPOUNDS FOR THE TREATMENT OF EYE PATHOLOGIES |
CN113876749A (en) * | 2021-10-28 | 2022-01-04 | 青岛大学附属医院 | Application of piceatannol in preparing medicine for preventing and/or treating herpes simplex virus infection |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4107396A1 (en) * | 1990-06-29 | 1992-01-02 | Bayer Ag | STYLE SYNTHASE GENES FROM VINEYARD |
US6197834B1 (en) | 1998-09-01 | 2001-03-06 | Northeastern Ohio Universities College Of Medicine | Method of inhibiting formation of infectious herpes virus particles |
-
1998
- 1998-09-01 US US09/145,039 patent/US6197834B1/en not_active Expired - Fee Related
-
1999
- 1999-08-20 AU AU55760/99A patent/AU746756B2/en not_active Ceased
- 1999-08-20 CA CA002342582A patent/CA2342582C/en not_active Expired - Fee Related
- 1999-08-20 WO PCT/US1999/019023 patent/WO2000012534A2/en active IP Right Grant
-
2000
- 2000-12-11 US US09/734,444 patent/US6355692B2/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599945B2 (en) | 2000-08-15 | 2003-07-29 | Northeastern Ohio Universities College Of Medicine | Methods for treating subjects infected with a herpes virus |
US20050267023A1 (en) * | 2002-08-09 | 2005-12-01 | Sinclair David A | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US7544497B2 (en) | 2003-07-01 | 2009-06-09 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US8846724B2 (en) | 2003-12-29 | 2014-09-30 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US9597347B2 (en) | 2003-12-29 | 2017-03-21 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US20060084085A1 (en) * | 2004-06-16 | 2006-04-20 | Sinclair David A | Methods and compositions for modulating Bax-mediated apoptosis |
US9241916B2 (en) | 2005-06-14 | 2016-01-26 | President And Fellows Of Harvard College | Cognitive performance with sirtuin activators |
Also Published As
Publication number | Publication date |
---|---|
US6197834B1 (en) | 2001-03-06 |
AU746756B2 (en) | 2002-05-02 |
WO2000012534A3 (en) | 2000-06-08 |
US6355692B2 (en) | 2002-03-12 |
CA2342582C (en) | 2009-10-27 |
CA2342582A1 (en) | 2000-03-09 |
WO2000012534A2 (en) | 2000-03-09 |
AU5576099A (en) | 2000-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6355692B2 (en) | Method of inhibiting formation of infectious microorganisms | |
US6099835A (en) | Method of using antiviral composition | |
US5484589A (en) | Anti-viral methods using RNAse and DNAse | |
Wilcox | Infectious bovine kerato-conjunctivitis: A review. | |
JP2002515410A (en) | Broad spectrum disinfecting and spermicidal compositions, devices and methods | |
US4256743A (en) | Inhibition of bone resorption with H1 -blocking antihistamines | |
US5232692A (en) | Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent | |
US7037945B2 (en) | Method of inhibiting formation of Neisseria gonorrhea and Neisseria meningiditis | |
Al-Salem et al. | Osteomyelitis and septic arthritis in sickle cell disease in the eastern province of Saudi Arabia | |
US6599945B2 (en) | Methods for treating subjects infected with a herpes virus | |
Grimwood et al. | Subinhibitory antibiotics reduce Pseudomonas aeruginosa tissue injury in the rat lung model | |
Moore | Observations pointing to the conjunctiva as the portal of entry in salmonella infection of guinea-pigs | |
Friis et al. | Isolation of Mycoplasma bovoculi from cases of infectious bovine keratoconjunctivitis | |
Vernon et al. | Chromogenic bacteria with a case report of a fatal infection caused by Serratia marcescens. | |
IE47574B1 (en) | Inhibiting growth of mycoplasmas | |
Wagner et al. | Decontamination of gnotobiotic mice experimentally monoassociated with Candida albicans | |
US7282599B2 (en) | Dithiocarbamate antiviral agents and methods of using same | |
Maestrone et al. | Prophylactic and therapeutic activity of rofenaid-40 in an experimental Escherichia coli airsac infection in chickens | |
Browning et al. | The chemotherapy of pyogenic infections with special reference to the antiseptic properties of acridine compounds | |
Schultz | The Bacteriophage: Its Prophylactic and Therapeutic Value: A Review | |
RU2245156C1 (en) | Method for preventing chlamydial gastroenteritis in calves | |
RU2301669C2 (en) | Using compounds of antiviral class for preparing agent for treatment and prophylaxis of respiratory tract viral infection | |
George et al. | Pathogenesis and clinical management of infectious bovine keratoconjunctivitis | |
RU2175557C1 (en) | Method of prophylaxis of inflammatory disease of upper respiratory tract | |
CN116059276A (en) | Pharmaceutical composition for resisting porcine epidemic diarrhea virus and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOCHERTY, JOHN;REEL/FRAME:011628/0358 Effective date: 20010302 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140312 |